Philadelphia Chromosome Positive Recruiting Phase 2 Trials for Ibrutinib (DB09053)

Also known as: Philadelphia chromosome positive

IndicationStatusPhase
DBCOND0046287 (Philadelphia Chromosome Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02997761Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic LeukemiaTreatment